NDA 21775-S018

SUPPLEMENT APPROVAL

Cubist Pharmaceuticals LLC
C/O Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Attention: Vamsidhara Dhulipala
Regulatory Liaison, Global Regulatory Affairs
351 Sumneytown Pike
PO box 1000, UG-2D68
North Wales, PA 19454

Dear Mr. Dhulipala:

Please refer to your supplemental new drug application (sNDA) dated and received on October 1, 2020, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ENTEREG (alvimopan) capsule.

This Changes Being Effected supplemental new drug application provides for changes to the Prescribing Information in the Boxed Warning, Warnings and Precautions, and Patient Counseling Information sections replacing ENTEREG REMS with the single shared system REMS (Alvimopan REMS). These changes are based on the approval of a SSS REMS for Alvimopan on December 19, 2019.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved effective on the date of this letter.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. If the content of labeling in SPL format initially submitted with this CBE labeling supplement is identical to the attached approved labeling, an additional submission of content of labeling in SPL format is not required.

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jacqueline LeeHoffman, Pharm.D, Safety Regulatory Project Manager, at 240-402-8689.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology (DG)
Office of Immunology and Inflammation (OII)
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling
  - Prescribing Information

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOYCE A KORVICK
11/17/2020 03:52:08 PM